121 related articles for article (PubMed ID: 2785847)
1. Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.
Sirotnak FM; Schmid FA; DeGraw JI
Cancer Res; 1989 Jun; 49(11):2890-3. PubMed ID: 2785847
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
3. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
Sirotnak FM; Otter GM; Schmid FA
Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
[TBL] [Abstract][Full Text] [Related]
4. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
Sirotnak FM; Moccio DM; Dorick DM
Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
[TBL] [Abstract][Full Text] [Related]
5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
7. Localized chemotherapy of Gardner's lymphosarcoma of C3H mice using combinations of carrier-sorbed antifolics and detoxicating tetrahydrofolates.
Motycka K; Slavík K; Balcarová A; Spacek P; Kubín M
Czech Med; 1981; 4(1-2):14-24. PubMed ID: 6973453
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
[TBL] [Abstract][Full Text] [Related]
9. Structural design, biochemical properties, and evidence for improved therapeutic activity of 5-alkyl derivatives of 5-deazaaminopterin and 5-deazamethotrexate compared to methotrexate in murine tumor models.
Sirotnak FM; Schmid FA; Otter GM; Piper JR; Montgomery JA
Cancer Res; 1988 Oct; 48(20):5686-91. PubMed ID: 3167828
[TBL] [Abstract][Full Text] [Related]
10. Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums.
Khokhar NZ; She Y; Rusch VW; Sirotnak FM
Clin Cancer Res; 2001 Oct; 7(10):3199-205. PubMed ID: 11595715
[TBL] [Abstract][Full Text] [Related]
11. Antitumor properties of a new folate analog, 10-deaza-aminopterin, in mice.
Sirotnak FM; DeGraw JI; Moccio DM; Dorick DM
Cancer Treat Rep; 1978 Jul; 62(7):1047-52. PubMed ID: 688246
[TBL] [Abstract][Full Text] [Related]
12. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1985 May; 69(5):551-3. PubMed ID: 4005878
[TBL] [Abstract][Full Text] [Related]
13. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
14. Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro.
Samuels LL; Moccio DM; Sirotnak FM
Cancer Res; 1985 Apr; 45(4):1488-95. PubMed ID: 3978616
[TBL] [Abstract][Full Text] [Related]
15. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
Currie VE; Warrell RP; Arlin Z; Tan C; Sirotnak FM; Greene G; Young CW
Cancer Treat Rep; 1983 Feb; 67(2):149-54. PubMed ID: 6825121
[TBL] [Abstract][Full Text] [Related]
17. Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts.
Brown DH; Braakhuis BJ; van Dongen GA; van Walsum M; Bagnay M; Snow GB
Anticancer Res; 1989; 9(6):1549-52. PubMed ID: 2627109
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
19. 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties.
Sirotnak FM; Schmid FA; Samuels LL; DeGraw JI
NCI Monogr; 1987; (5):127-31. PubMed ID: 2448650
[TBL] [Abstract][Full Text] [Related]
20. Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
Cao S; Abraham A; Nair MG; Pati R; Galivan JH; Hausheer FH; Rustum YM
Clin Cancer Res; 1996 Apr; 2(4):707-12. PubMed ID: 9816221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
